Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros













Base de datos
Intervalo de año de publicación
1.
Genes Chromosomes Cancer ; 62(12): 732-739, 2023 12.
Artículo en Inglés | MEDLINE | ID: mdl-37530573

RESUMEN

Rhabdomyosarcomas (RMS) constitute a heterogeneous spectrum of tumors with respect to clinical behavior and tumor morphology. The paternal uniparental disomy (pUPD) of 11p15.5 is a molecular change described mainly in embryonal RMS. In addition to LOH, UPD, the MLPA technique (ME030kit) also determines copy number variants and methylation of H19 and KCNQ1OT1 genes, which have not been systematically investigated in RMS. All 127 RMS tumors were divided by histology and PAX status into four groups, pleomorphic histology (n = 2); alveolar RMS PAX fusion-positive (PAX+; n = 39); embryonal RMS (n = 70) and fusion-negative RMS with alveolar pattern (PAX-RMS-AP; n = 16). The following changes were detected; negative (n = 21), pUPD (n = 75), gain of paternal allele (n = 9), loss of maternal allele (n = 9), hypermethylation of H19 (n = 6), hypomethylation of KCNQ1OT1 (n = 6), and deletion of CDKN1C (n = 1). We have shown no difference in the frequency of pUPD 11p15.5 in all groups. Thus, we have proven that changes in the 11p15.5 are not only specific to the embryonal RMS (ERMS), but are often also present in alveolar RMS (ARMS). We have found changes that have not yet been described in RMS. We also demonstrated new potential diagnostic markers for ERMS (paternal duplication and UPD of whole chromosome 11) and for ARMS PAX+ (hypomethylation KCNQ1OT1).


Asunto(s)
Rabdomiosarcoma Alveolar , Rabdomiosarcoma Embrionario , Rabdomiosarcoma , Humanos , Rabdomiosarcoma Embrionario/genética , Rabdomiosarcoma Embrionario/patología , Rabdomiosarcoma/genética , Rabdomiosarcoma Alveolar/genética , Metilación de ADN , Disomía Uniparental , Cromosomas
2.
Neuro Endocrinol Lett ; 31 Suppl 2: 120-3, 2010.
Artículo en Inglés | MEDLINE | ID: mdl-21187818

RESUMEN

OBJECTIVES: The work objective was to monitor nutritional habits in the observed group of professional soldiers with the focus on eating food with the content of antioxidant carriers. Then to show present state of health and nutrition in the group on the basis of anthropometric measurements and biochemical examinations and finally to observe the level of antioxidant vitamins in the observed group of professional soldiers. METHODS: The group included 171 healthy individuals, 152 men and 19 women. Their average age was 34.2±7.9 years. The venous blood was taken for biochemical examinations in all individuals on a fast. Anthropometric measurements (weight, height, caliperation, waist circumferences), blood pressure and pulse were taken continually in all individuals. Simple questionnaires were administered to all participants for the complete evaluation of present health and for the registration of eating habits of the observed persons. RESULTS: The study results show that retinol and a-tocoferol levels in the observed group were within a normal range. The average concentration of vitamin C in this group was 54 mmol/l and reached nearly the values given in other European countries. But concentrations of ß-caroten and lycopen in serum were up to 50% lower in comparison with concentrations in population in the countries of West Europe. Higher vitamin C and ß caroten serum levels were found in individuals who respond in a questionnaire they eat fruit and vegetables or supplements of vitamin preparations every day. Statistically lower levels of vitamin C, ß karoten and lycopen in the group of obese people (compared with the group of normal weight people) show decreased level of antioxidant protection of the organism and the risk of cardiovascular diseases. CONCLUSIONS: The results show that it is necessary to ensure optimal food not only with an energetic diet value but also with a proper input of antioxidant carriers in the form of fresh vegetables and fruit every day.


Asunto(s)
Estado de Salud , Personal Militar , Estado Nutricional , Vitaminas/sangre , Adulto , Ácido Ascórbico/sangre , Carotenoides/sangre , República Checa , Dieta , Femenino , Encuestas Epidemiológicas , Humanos , Licopeno , Masculino , Vitamina A/sangre , alfa-Tocoferol/sangre , beta Caroteno/sangre
3.
Virchows Arch ; 456(5): 463-72, 2010 May.
Artículo en Inglés | MEDLINE | ID: mdl-20405298

RESUMEN

Childhood rhabdomyosarcoma (RMS) has two major histological subtypes: alveolar (aRMS) and embryonal. The aim of the study was to monitor minimal disseminated disease (MDD) using real-time quantitative reverse-transcription PCR (RQ-RT-PCR) of the PAX3-FKHR, PAX7-FKHR fusion genes and myoD1 gene. We prepared an assay using RQ-RT-PCR for a quantitative assessment of MDD in aRMS by using hydrolysis probe for quantification of PAX3-FKHR, PAX7-FKHR and myoD1 genes and beta-2-microglobulin housekeeping gene. Primary tumor samples (44), samples of local recurrences (26) from 48 patients with aRMS were examined by nested RT-PCR and RQ-RT-PCR techniques. Additionally, bone marrow samples (115), peripheral blood progenitor cell samples (27), and peripheral blood samples (25) from 33 aRMS patients were tested. PAX3/7-FKHR and myoD1 transcripts proved to be a sensitive tool for detection of MDD in RMS. We were able to identify 15/25 patients with bone marrow (BM) involvement at the time of presentation using RQ-RT-PCR. We analyzed PAX3-FKHR or PAX7-FKHR expression during the course of the disease. The RQ-RT-PCR results correlated well with nested RT-PCR results (p < 0.0001). The presence of metastases is the most adverse prognostic factor in RMS, and bone marrow is a frequent site of the tumor dissemination in RMS, especially in aRMS. Our results detecting the fusion transcripts or myoD1 transcript in the BM or peripheral blood suggest that patients with positive findings are at high risk of the tumor progression.


Asunto(s)
Biomarcadores de Tumor/análisis , Médula Ósea/patología , Factores de Transcripción Forkhead/análisis , Factor de Transcripción PAX7/análisis , Rabdomiosarcoma Alveolar/patología , Rabdomiosarcoma/patología , Adolescente , Médula Ósea/química , Niño , Preescolar , Femenino , Proteína Forkhead Box O1 , Humanos , Lactante , Masculino , Proteína MioD/genética , Recurrencia Local de Neoplasia/patología , Factor de Transcripción PAX3 , Factores de Transcripción Paired Box/análisis , Pronóstico , Proteínas Recombinantes de Fusión/análisis , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa/métodos , Rabdomiosarcoma/química , Rabdomiosarcoma/genética , Rabdomiosarcoma/mortalidad , Rabdomiosarcoma Alveolar/química , Rabdomiosarcoma Alveolar/genética , Rabdomiosarcoma Embrionario/genética , Rabdomiosarcoma Embrionario/patología , Adulto Joven
4.
Leuk Lymphoma ; 47(9): 1881-4, 2006 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-17065001

RESUMEN

The objective of this study was to evaluate the efficacy of 2-chlorodeoxyadenosine (2-CdA), a purine nucleoside analog, in treating recurrent Langerhans cell histiocytosis (LCH) in children. This study retrospectively analysed the clinical records of 13 patients who were seen in the department for recurrent LCH. These patients were treated consecutively with 2-CdA chemotherapy between July 1997 and May 2005. Median age at diagnosis was 4 years 7 months and median pre-treatment duration of disease was 16.4 months. Four children received 0.1 mg kg-1 per day for 7 days and nine patients 5 mg m-2 per day for 5 days, repeated every 21 days. The maximum number of courses of 2-CdA per patient was limited to six. Seventy-six courses of 2-CdA were administered without difficulty. All 13 patients (100%) had a clinical response documented by radiographic investigation. Nine patients did not require additional therapy and remain in complete remission (CR). Four remaining children are currently disease-free after receiving other therapy as irradiation (two cases) or maintenance chemotherapy (vinblastine, prednisone and 6-mercaptopurine) (one case) or chemotherapy (vinblastine) + irradiation (one child) ( Table I). Hematologic toxicity was minimal and no infectious complications were documented. Median follow-up after initiation of 2-CdA treatment was 4 years 3 months (range 7 months - 8 years 2 months). This experience confirms the reported efficacy of 2-CdA in the treatment of LCH. However, further studies are needed to determine the role of this agent in high-risk patient who did not achieve complete remission after 2-CdA administration.


Asunto(s)
Cladribina/uso terapéutico , Histiocitosis de Células de Langerhans/tratamiento farmacológico , Inmunosupresores/uso terapéutico , Recurrencia Local de Neoplasia/tratamiento farmacológico , Adolescente , Niño , Preescolar , Supervivencia sin Enfermedad , Histiocitosis de Células de Langerhans/patología , Humanos , Lactante , Recurrencia Local de Neoplasia/patología , Inducción de Remisión , Estudios Retrospectivos , Resultado del Tratamiento
5.
Eur J Nucl Med Mol Imaging ; 33(9): 1025-31, 2006 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-16565847

RESUMEN

PURPOSE: The aim of this study was to perform a prospective, blinded comparison of( 18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) and conventional staging methods (CSMs) for initial staging of children and adolescents with Hodgkin's disease (HD). METHODS: Over a period of 4 years, 55 children and adolescents with HD (mean age 15.5 years, range 3.9-18.9 years) were prospectively recruited into the study. They underwent 61 FDG-PET studies using a dedicated whole-body PET scanner as a part of their initial staging work-up. PET findings were correlated with the results of CSMs, including computed tomography (CT), ultrasound, bone scanning and bone marrow examination. Discordant findings were resolved by magnetic resonance imaging or clinical follow-up (range 2-47 months). RESULTS: PET correctly changed the staging in 15% of patients (seven upstagings, two downstagings). Only two out of 61 patients (3%) were not accurately staged by PET; in these children, PET missed small lymphoma nodules detected on lung CT. The sensitivity of PET and CSMs for pretreatment staging was 96.5% and 87.5%, respectively; specificity was 100% and 60%, and accuracy, 96.7% and 85.2%, respectively. Upon combination of FDG-PET and lung CT, the diagnostic accuracy reached 100% in our series. CONCLUSION: Our study showed that whole-body FDG-PET is an efficient and useful method for the initial staging of children with HD. FDG-PET in combination with lung CT should be recommended as a screening method prior to other conventional imaging modalities to plan a rational staging protocol. Large multicentre prospective studies are necessary to verify this conclusion.


Asunto(s)
Fluorodesoxiglucosa F18 , Enfermedad de Hodgkin/diagnóstico por imagen , Enfermedad de Hodgkin/patología , Estadificación de Neoplasias/métodos , Radiofármacos , Adolescente , Niño , Preescolar , Femenino , Radioisótopos de Flúor , Humanos , Pulmón/diagnóstico por imagen , Masculino , Tomografía de Emisión de Positrones , Estudios Prospectivos , Método Simple Ciego , Tomografía Computarizada por Rayos X
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA